Impact
CURE-SHOCK is expected to generate impact far beyond evaluating a promising new treatment for shock. By bringing together expertise from cardiology, intensive care, burn medicine, and translational research, the project aims to advance scientific knowledge, improve patient care and strengthen Europe's research innovation landscape.
Scientific and Clinical Impact
- Advancing our understanding of DPP3’s role in circulatory shock
- Generating new evidence for the development and clinical validation of innovative biotechnology based therapies in critical care
- Strengthening research infrastructure across biotechnology, pharmaceuticals, medical technologies and digital health
- Expanding clinical trial networks across Europe and Ukraine
Societal Impact
- Potentially saving tens of thousands of lives annually in the EU
- Improving quality of life for survivors and their families
- Accelerating access to innovative treatments for circulatory shock
- Supporting better care pathways and inclusion for underserved patient groups
Economic and Technological Impact
- Shortening the path from clinical research to market
- Attracting investment, creating skilled jobs and strengthening the competitiveness of European biotechnology companies
- Supporting the development and adoption of innovative therapies and companion diagnostics
- Strengthening European leadership and strategic autonomy in critical health technologies